公开(公告)号：US20250082611A1

公开(公告)日：2025-03-13

申请号：US18580781

申请日：2022-07-20

Applicant: Novartis AG

Inventor： Laura COLEMAN ,  Christopher FARADY ,  Ewa GATLIK ,  Matthias SCHIEKER

IPC: A61K31/426 ,  A61P19/02

Abstract: The present disclosure relates to the field of pharmacy, particularly to an NLRP3 inhibitor for use in the treatment of osteoarthritis. The disclosure also relates to an NLRP3 inhibitor or a pharmaceutical combination comprising an NLRP3 inhibitor, and at least one further therapeutic agent, for use in the treatment of osteoarthritis; to a method for the treatment of osteoarthritis that involves administering an NLRP3 inhibitor or the combination; and to the use of an NLRP3 inhibitor or the combination for the manufacture of a medicament for the treatment of osteoarthritis.

公开(公告)号：US20220251067A1

公开(公告)日：2022-08-11

申请号：US17574820

申请日：2022-01-13

Applicant: Novartis AG

Inventor： Christopher FARADY ,  Nina GOMMERMANN ,  Philipp JANSER ,  Angela MACKAY ,  Henri MATTES ,  Nichola SMITH ,  Catherine Fooks SOLOVAY ,  Nikolaus Johannes STIEFL ,  Eric VANGREVELINGHE ,  Juraj VELCICKY ,  Anette von MATT

IPC: C07D401/12 ,  C07D237/14 ,  C07D237/20 ,  C07D403/12 ,  C07D413/12 ,  C07D451/04

Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.

公开(公告)号：US20210308140A1

公开(公告)日：2021-10-07

申请号：US17259252

申请日：2019-07-23

Applicant: Novartis AG

Inventor： Christopher FARADY ,  Nina GOMMERMANN ,  Philipp JANSER ,  Angela MACKAY ,  Henri MATTES ,  Nikolaus Johannes STIEFL ,  Juraj VELCICKY

IPC: A61K31/53 ,  A61K45/06 ,  A61K31/616 ,  C07D495/14 ,  C07D513/14

Abstract: The present invention relates to novel thienopyrrolotriazinacetamide compounds of Formula (I): wherein R1, R2 and R3 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of disease and disorders mediated by NLRP3.